Prevention of Anal Condyloma with Quadrivalent Human Papillomavirus Vaccination of Older Men Who Have Sex with Men

Background The quadrivalent human papillomavirus vaccine (qHPV) is FDA-approved for use in males 9 to 26 years old to prevent anogenital condyloma. The objective of this study is to determine if qHPV is effective at preventing anal condyloma among men who have sex with men (MSM) aged 26 years and older. Methods This post-hoc analysis of a nonconcurrent cohort study evaluated 210 patients without history of anal condyloma and 103 patients with previously-treated anal condyloma recurrence-free for at least 12 months prior to vaccination/time zero. We determined the rate of anal condyloma development in vaccinated versus unvaccinated patients. Results 313 patients with mean age 42 years were followed for median 981 days. During 773.6 person-years follow-up, condyloma developed in 10 (8.6%) vaccinated patients (incidence of 3.7 per 100 person-years) and 37 (18.8%) unvaccinated patients (incidence 7.3 per 100 person-years; p = 0.05). Multivariable hazards ratio showed that qHPV was associated with decreased risk of anal condyloma development (HR 0.45; 95% CI 0.22–0.92; p = 0.03). History of anal condyloma was associated with increased risk of anal condyloma development (HR 2.28; 95% CI 1.28–4.05; p = 0.005), as was infection with oncogenic HPV (HR 3.87; 95% CI 1.66–9.03; p = 0.002). Conclusions Among MSM 26 years of age and older with and without history of anal condyloma, qHPV reduces the risk of anal condyloma development. A randomized controlled trial is needed to confirm these findings in this age group.

[1]  H. Jessen,et al.  Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. , 2011, The New England journal of medicine.

[2]  H. Jessen,et al.  Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males. , 2013, Vaccine.

[3]  S. Goldstone,et al.  Should I or shouldn't I: decision making, knowledge and behavioral effects of quadrivalent HPV vaccination in men who have sex with men. , 2011, Vaccine.

[4]  J. Kaldor,et al.  Risk Factors for Genital and Anal Warts in a Prospective Cohort of HIV-Negative Homosexual Men: The HIM Study , 2006, Sexually transmitted diseases.

[5]  Daron G Ferris,et al.  Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data , 2012, BMJ : British Medical Journal.

[6]  H. Larsen,et al.  Quality of life of homosexual males with genital warts: a qualitative study , 2010, BMC Research Notes.

[7]  D. Lowy,et al.  Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. , 2012, Vaccine.

[8]  I. Bravo,et al.  Papillomaviruses , 2006, Journal of Cancer Research and Clinical Oncology.

[9]  Leslie Carol Botha.  FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). , 2010, MMWR. Morbidity and mortality weekly report.

[10]  K. Sherman,et al.  Risk Factors for Incident and Recurrent Condylomata Acuminata Among Women: A Population‐Based Study , 1998, Sexually transmitted diseases.

[11]  I. Dal Conte,et al.  Immunostimulation to reduce recurrence after surgery for anal condyloma acuminata: a prospective randomized controlled trial , 2009, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[12]  K. Swedish,et al.  The Changing Picture of High-grade Anal Intraepithelial Neoplasia in Men Who Have Sex With Men: The Effects of 10 Years of Experience Performing High-resolution Anoscopy , 2011, Diseases of the colon and rectum.

[13]  Ross D. Cranston,et al.  Age-Specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. , 2004, The Journal of infectious diseases.

[14]  N. Demartines,et al.  Human Papilloma Virus Type and Recurrence Rate After Surgical Clearance of Anal Condylomata Acuminata , 2009, Sexually transmitted diseases.

[15]  Yurii B. Shvetsov,et al.  Acquisition of anal human papillomavirus (HPV) infection in women: the Hawaii HPV Cohort study. , 2008, The Journal of infectious diseases.

[16]  Yurii B. Shvetsov,et al.  Duration and clearance of anal human papillomavirus (HPV) infection among women: the Hawaii HPV cohort study. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  S. Factor,et al.  Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  H. Jessen,et al.  HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. , 2011, The New England journal of medicine.

[19]  A. Giuliano,et al.  Risk factors for incident condyloma in a multinational cohort of men: the HIM study. , 2012, The Journal of infectious diseases.